Suchergebnisse - "Yoshikawa, Yuki"

PubPharm (6)

1

Attenuation of SRC Kinase Activity Augments PARP Inhibitor-mediated Synthetic Lethality in BRCA2-altered Prostate Tumors

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2021

von Chakraborty, G. | Patail, N. | Hirani, R. | +12

2

Risk stratification for the prediction of overall survival could assist treatment decision-making at diagnosis of castration-resistant prostate cancer : a multicentre collaborative study in Japan

enthalten in: BJU international | 2021

von Uchimoto, T. | Komura, K. | Fukuokaya, W. | +18

3

Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma

enthalten in: Oncology | 2021

von Ando, Y. | Kawaoka, T. | Amioka, K. | +28

4

Clinical Outcomes of 2nd- and 3rd-Line Regorafenib for Advanced Hepatocellular Carcinoma

enthalten in: Oncology | 2021

von Naruto, K. | Kawaoka, T. | Amioka, K. | +32

5

Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer

enthalten in: Molecular oncology | 2020

von Mazzu, Y. | Armenia, J. | Nandakumar, S. | +8

6

Prognostic impact of C-reactive protein-albumin ratio for the lethality in castration-resistant prostate cancer

enthalten in: Medical oncology (Northwood, London, England) | 2019

von Uchimoto, T. | Komura, K. | Fujiwara, Y. | +19

1
[1]